Tony Coles, M.D., Elected to Regeneron Board of Directors

Tuesday, January 31, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

TARRYTOWN, N.Y., Jan. 31, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that

it has elected Tony Coles, M.D., to its Board of Directors. 

"Tony is an entrepreneurial life sciences leader with significant experience in biopharmaceutical development and commercialization," said P. Roy

Vagelos, M.D., Chairman of the Regeneron Board of Directors. "We are pleased to welcome him to the Regeneron Board and believe his experience as a physician, commercial leader and chief executive will be invaluable as we continue to bring new and important medicines to market."

"I am delighted to be joining Regeneron at this exciting time for the company," said Dr. Coles. "With three commercialized medicines, two important upcoming product launches and an innovative pipeline across many therapeutic areas, Regeneron is uniquely positioned to bring important advances to people with serious diseases."

Dr. Coles was nominated to become a member of the Regeneron Board by Sanofi. Under the terms of an investor agreement between Regeneron and Sanofi, Sanofi gained the right to nominate a single independent director to the Regeneron Board when it reached 20 percent ownership of Regeneron's total outstanding capital stock. 

Dr. Coles is Chairman and Chief Executive Officer of Yumanity Therapeutics, a company focused on transforming drug discovery for neurodegenerative diseases. Previously, Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, an oncology-focused biopharmaceutical company, which was acquired by Amgen in 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer and a member of the board of directors of NPS Pharmaceuticals. Before joining NPS, Dr. Coles served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company and Vertex Pharmaceuticals. Dr. Coles is a director of McKesson Corporation and Chairman of the Board of CRISPR Therapeutics. He is also a member of the board of trustees for Johns Hopkins Medicine. Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a Research Fellow at Harvard Medical School. He earned his M.D. from Duke University, a master's degree in public health from Harvard University and an undergraduate degree from Johns Hopkins University.

About Regeneron Pharmaceuticals, Inc.Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit or follow @Regeneron on Twitter.

Media Contact at Regeneron: Hala MirzaPhone: 914.847.3422E-Mail:

To view the original version on PR Newswire, visit:

SOURCE Regeneron Pharmaceuticals, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store